Latest news

• NICE gives Bayer's Elyea a provisional 'no' for first-line use

  NICE gives Bayer's Elyea a provisional 'no' for first-line use. Company says recommendation goes against Royal College guidance for BRVO. ... NICE's next appraisal committee meeting on Eylea and its use in BRVO will take place in July, with final

• Bayer's Eylea cleared for wider use in Europe

  macular oedema following branch retinal vein occlusion (BRVO), while more than 50% of patients in the Eylea arm gained at least three lines of vision. ... BRVO is a common cause of visual impairment in the elderly and is around three times more common

• Germany's IQWiG delivers bad news for Bayer’s Eylea

  Bayer has also filed an application to extend the indications of its ophthalmic drug Eylea in Europe to include use in patients with branch retinal vein occlusion (BRVO), a leading cause

• Bayer files eye drug Eylea for new use in EU

  BRVO is around three times more common than CRVO so could provide a further fillip to growth momentum if approved. ... BRVO is a common retinal vascular disorder with an estimated 14 million people affected worldwide," said Joerg Moeller, head of global

• NICE backs new use for Bayer’s Eylea

  Lucentis has a slightly expanded indication, which also covers branch retinal vein occlusion (BRVO), although only if treatment involving the use of lasers to seal blood vessels in the eye has